Alnylam to Webcast Presentations at Upcoming December Investor Conferences
Evercore ISI 2nd Annual
HealthCONx Conferenceon Wednesday, December 4, 2019at 1:15 pm ETat the Four Seasons Hotelin Boston
Piper Jaffray31st Annual Healthcare Conference on Thursday, December 5, 2019at 9:00 am ETat the Lotte New York Palace Hotelin New York City
A live audio webcast of each presentation will be available on the Investors section of the Company’s website, www.alnylam.com. A replay will be available on the Alnylam website within 48 hours after each event.
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), approved in the U.S., EU,
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)